Tag Archives: Cory Kasimov

J.P. Morgan Keeps Their Sell Rating on Puma Biotechnology (PBYI)

J.P. Morgan analyst Cory Kasimov maintained a Sell rating on Puma Biotechnology (PBYI – Research Report) on August 8 and set a price target of $13. The company’s shares closed on Friday at $11.16, close to its 52-week low of

Jounce Therapeutics Inc (JNCE) Gets a Sell Rating from J.P. Morgan

In a report issued on August 7, Cory Kasimov from J.P. Morgan maintained a Sell rating on Jounce Therapeutics Inc (JNCE – Research Report). The company’s shares closed on Friday at $4.20. According to TipRanks.com, Kasimov is a 4-star analyst

J.P. Morgan Thinks Moderna Inc’s Stock is Going to Recover

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Moderna Inc (MRNA – Research Report) on August 7 and set a price target of $24. The company’s shares closed on Friday at $13.33, close to its 52-week low of

Allogene Therapeutics Inc (ALLO) Receives a Hold from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics Inc (ALLO – Research Report) on August 7 and set a price target of $29. The company’s shares closed on Friday at $31.18. According to TipRanks.com, Kasimov is

Global Blood Therapeutics (GBT) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) on August 7 and set a price target of $75. The company’s shares closed on Friday at $48.79. According to TipRanks.com, Kasimov is

J.P. Morgan Sticks to Their Buy Rating for Ultragenyx Pharmaceutical, Inc. (RARE)

In a report issued on August 1, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. (RARE – Research Report), with a price target of $75. The company’s shares closed on Friday at $55.66. According to